IP Verse

Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan - EP2861210

The patent EP2861210 was granted to Ipsen Biopharm on May 3, 2017. The application was originally filed on Jun 12, 2013 under application number EP13731230A. The patent is currently recorded with a legal status of "Revoked".

EP2861210

IPSEN BIOPHARM
Application Number
EP13731230A
Filing Date
Jun 12, 2013
Status
Revoked
May 20, 2022
Grant Date
May 3, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSFeb 5, 2018D YOUNGADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS8147867
EXAMINATIONWO2012146610
EXAMINATIONWO2013138371

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- C Yoo ET AL, "A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer", British Journal of Cancer, GB, (20091013), vol. 101, no. 10, doi:10.1038/sj.bjc.6605374, ISSN 0007-0920, pages 1658 - 1663, XP055326781
OPPOSITION- "Highlights of Prescribing Information) for CAMPTOSAR (irinotecan)", Pfizer Injectables, (20120700), pages 1 - 38, XP055462062-
OPPOSITION- "Highlights of Prescribing Information for FUSILEV (levoleucovorin)", Spectrum Pharmaceuticals, Inc., (20080000), XP055461994-
OPPOSITION- "Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5- Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer", Clinical Trials Identifier: NCT01494506, (20130125), URL: https://clinicaltrials.gov/archive/NCT01494506/2013_01_25, XP055462084-
OPPOSITION- ZANIBONI A et al., "FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study", Cancer Chemother Pharmacol, (20120000), vol. 69, pages 1641 - 1645, XP035062678
OPPOSITION- INFANTE et al., "Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors", Cancer Chemother Pharmacol, (20120000), vol. 70, no. 5, pages 699 - 705, XP035132528
OPPOSITION- YOO et al., "A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer", Br J Cancer, (20090000), vol. 101, pages 1658 - 1663, XP055326781
OPPOSITION- TAÏEB J et al., "FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study", Ann Oncol, (20070000), vol. 18, pages 498 - 503, XP055462003
OPPOSITION- HOSKINS J M et al., "UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters", J Natl Cancer Inst, (20070000), vol. 99, pages 1290 - 5, XP055022025
OPPOSITION- GEBBIA V et al., "Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma : A Multicenter Experience of the Gruppo Oncologico Italia Meridionale", Am J Clin Oncol, (20100000), vol. 33, pages 461 - 464, XP055461997
OPPOSITION- CHEN L et al., "phase i study of liposome encaspulated irinotecan (pep02) in advanced", J Clin Oncol, (20080000), vol. 26, page 2565, XP055462011
OPPOSITION- KO A H et al., "A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer.", J Clin Oncol, (20110000), vol. 29, no. 15, page 4069, XP055462083
OPPOSITION- WATERHOUSE et al., "Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy", Nanomedicine, (20110000), vol. 6, no. 9, pages 1645 - 1654, XP055462015
OPPOSITION- NEUZILLET C et al., "FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts", World J Gastroenterol, (20120900), vol. 18, no. 33, pages 4533 - 4541, XP055075357
OPPOSITION- TSAI C-S et al., "Nanovector-based therapies in advanced pancreatic cancer", J Gastrointest Oncol, (20110000), vol. 2, no. 3, pages 185 - 194, XP055075231

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents